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The hydroxylation to 25-hydroxy vitamin D (25(OH)D) occurs in the liver and the impact of
liver disease on vitamin D is unclear. This study evaluated the relationship between vitamin
D concentrations and hepatic histopathology, seasonality and patient characteristics in well-
characterized patients having undergone a liver biopsy.
Method
25(OH)D was measured post-hoc in pre-treatment serum from 331 North European patients
with chronic HCV genotype 2 or 3 infection (NORDynamIC study). Liver biopsies were
scored for fibrosis and inflammation according to the Ishak protocol, and graded for steato-
sis. Non-invasive markers of hepatic fibrosis as well as baseline viral and host characteris-
tics, including genetic polymorphisms rs2228570, rs7975232, and rs10877012 were also
evaluated.
Results
Mean 25(OH)D concentration was 59 ±23 nmol/L, with 41% having values <50 nmol/L and
6% were <30 nmol/L. 25(OH)D correlated with fibrosis (r = -0.10, p�0.05) in univariate but
not in multivariate analyses. No association was observed between 25(OH)D and hepatic
inflammation, but with steatosis in HCV genotype 2 infected patients. None of the genetic
polymorphisms impacted on 25(OH)D levels or fibrosis. 25(OH)D levels were significantly
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inversely correlated to BMI (r = -0.19, p = 0.001), and was also associated with season and
non-Caucasian ethnicity.
Conclusion
Fibrosis was not independently associated with 25(OH)D concentration and no association
was seen with hepatic inflammation, but HCV genotype 2 infected patients with moderate-
to-severe steatosis had lower 25(OH)D levels compared to those without steatosis. A high
percentage had potential risk of 25(OH)D deficiency, and BMI, seasonality and ethnicity
were independently associated with 25(OH)D as previously reported.
Introduction
Vitamin D is essential for bone mineralization by regulating calcium and phosphate levels in
blood, and deficiency can lead to rickets and osteomalacia [1]. Lately increasing evidence also
suggests importance of vitamin D regarding infectious diseases, malignancies, autoimmune
diseases, obesity, type 2 diabetes, liver diseases and risk of death [2, 3], although these latter
associations have been questioned, especially regarding possible causality [4].
The majority of vitamin D is endogenously synthesized from D7-dehydrocholesterol upon
exposure of skin to ultraviolet (UV) radiation, but can also be ingested orally by vitamin D
rich nutrients. As UV radiation in the northern latitudes is insufficient for production during
winter, stored vitamin D, sufficient dietary intake, and/or supplementation are needed for
maintenance of adequate levels during this season [5]. Vitamin D requires two successive
hydroxylation reactions to be activated: i) in the liver by the enzyme cholecalciferol 25-hydrox-
ylase to 25-hydroxy vitamin D (25(OH)D) also known as calcifediol and ii) mainly in the kid-
neys by cytochrome p450 27B1 (CYP27B1; also known as 1-alpha-hydroxylase) to
1,25-dihydroxy vitamin D also referred to as calcitriol. Calcitriol signals through the vitamin D
receptor (VDR), influences the expression of a multitude of genes, and is expressed in most
human cell types indicating a broader effect than regulation of bone mineralization [6]. Calci-
triol has a short half-life and varies in concentration. In contrast 25(OH)D is stable and more
accurately reflects vitamin D status, and therefore is preferred for detecting vitamin D defi-
ciency [7]. Vitamin D is fat soluble, and higher body mass index (BMI) is known to associate
with lower systemic 25(OH)D concentrations [2].
The definition of vitamin D deficiency is controversial. The Institute of Medicine (IOM)
has defined two cut-offs: i)�50 nmol/L 25(OH)D where deficiency is highly unlikely, and ii)
<30 nmol/L where it is likely [8]. The Endocrine Society has an additional cut-off at<75
nmol/L, with concentrations between 50–75 considered insufficient [9]. In this study we used
the definition by IOM [10].
Vitamin D reportedly affects both innate and adaptive immunity, and has been extensively
studied in diseases entailing inflammation [11], including chronic hepatitis C virus (HCV)
infection. Vitamin D has been reported to have an in vitro antiviral effect on HCV [12, 13] and
previous publications reports lower likelihood of achieving a cure, i.e. sustained virologic
response (SVR), following interferon-based therapy in the presence of low systemic concentra-
tions of 25(OH)D [14–16]. A recent meta-analysis demonstrates a significant association
between 25(OH)D concentration and fibrosis. The analysis was composed of twelve studies of
which eight could observe an association, whereas four could not. Importantly only one study
reported having HCV genotype 2 or 3 infected participants [17]. Many studies in other chronic
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liver diseases have also noted decreasing vitamin D levels with cirrhosis [18]. Low vitamin D
levels has also been linked with steatosis and liver inflammation [10, 19].
Several genetic polymorphisms associated with 25 (OH) vitamin D signaling and metabo-
lism have been studied in patients with chronic hepatitis C. The Vitamin D receptor (VDR)
contains several and among them a combined genotype, in strong linkage disequilibrium,
referred to as CCA haplotype. This haplotype comprises rs1544410 (BsmI) C, rs7975232
(ApaI) C and rs731236 (TaqI) A alleles and has been associated with liver fibrosis progression
and response to interferon and ribavirin treatment [20, 21]. Another VDR single-nucleotide
polymorphism (SNP) in exon 2, rs2228570 (FokI, aka rs10735810), is located within a start
codon where the presence of a C allele instead of T allele leads to the initiation of translation at
an alternative site, resulting in a shorter, reportedly less active receptor [22]. There are also sev-
eral single nucleotide polymorphisms (SNPs) associated with the metabolism of vitamin D, of
which rs10877012 is situated in the CYP27B-1260 gene promotor. In a study by Lange et al,
the A allele was associated with higher serum concentration of the active form of vitamin D,
1.25(OH)D and SVR [23].
As the first hydroxylation step activating vitamin D to 25(OH)D occurs in the liver and as
the impact of hepatic histopathology on 25(OH)D levels remains unclear, this study thus
aimed at evaluating the vitamin D concentrations in relation to liver histopathology, as well as
other baseline characteristics, in very well-characterized patients enrolled in a north European
multicenter HCV therapeutic trial (NORDynamIC), where pre-treatment liver biopsies were
mandatory [24] and where a relatively large proportion had advanced liver fibrosis.
Method
Study design and population
The study population was derived from the NORDynamIC study in which 382 treatment-naïve,
HCV genotype 2 or 3 chronically infected patient were enrolled. The study was conducted
between February 2004 and November 2005 at 31 centers in Sweden, Denmark, Finland and
Norway, located between latitudes 55–62˚ [24]. All patients had compensated liver disease, were
adults and had no co-infection with hepatitis B virus or human immunodeficiency virus (HIV).
In this phase III, open label, randomized, multicenter, investigator-initiated treatment study
patients were randomized to receive either 12 or 24 weeks of treatment with 180 μg of peg-inter-
feron (Peg-IFN) α-2a once weekly and 800 mg/day ribavirin. Pre-treatment serum samples
were stored at -80˚C. Pre-treatment liver biopsies were mandatory and were available for assess-
ment for 354 of 382 patients. Pre-treatment serum samples for 25(OH)D analysis were available
from 331 of these 354 patients, which comprised the study population. Baseline characteristics
and treatment response are detailed in Table 1. Forty-three patients (13% of the total study pop-
ulation) had cirrhosis, 313 of 331 patients were of Caucasian ethnicity, 60% of participants were
male. All concomitant medication was documented through the study, and vitamin D supple-
mentation was only used by four patients and only in multivitamin tablets. Child-Pugh B and C
cirrhotic patients, i.e. decompensated cirrhosis, were excluded from the NORDynamIC study
as interferon therapy is contraindicated in these patients.
Assessments of liver biopsies
The liver biopsies were centrally staged for fibrosis in a blinded fashion according to the Ishak
protocol by two independent experienced observers (J.We. and M.L.). When diverging results
were obtained, renewed assessments were performed and a consensus score was agreed upon.
Ishak has seven different stages of fibrosis, i.e. stages 0–6. In this study, absence of fibrosis is
defined as Ishak stage 0, mild fibrosis as stage 1–2, moderate fibrosis as stage 3–4 and cirrhosis
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as stage 5–6. Inflammation was assessed using the Ishak protocol and are presented as grade of
interface hepatitis (0–4), lobular inflammation (0–4), portal inflammation (0–4) or a sum of all
these inflammation scores. Steatosis was also graded as absent (grade 0), mild (less than 30% of
hepatocytes involved, grade 1), moderate (30–70% of hepatocytes involved, grade 2) or severe
(>70% of hepatocytes involved, grade 3).
Table 1. Characteristics of the 331 patients included in the study and differences in characteristics according to 25 (OH) vitamin D sufficiency, potential risk of
deficiency and risk of deficiency.
Feature All patients >50 nmol/L,
sufficiency
30–50 nmol/L, potentially
at risk of deficiency
<30 nmol/L, risk of
deficiency
n = 331 n = 197 (59.5%) n = 113 (34.1%) n = 21 (6.3%) Unadjusted
P-value
Epidemiological features
Age, mean (SD), years 41.9 (10.8) 41.7 (11.0) 41.4 (10.9) 46.3 (8.6) 0.16
Sex male n(%) 200 (60.4) 116 (59) 71 (63) 13 (62) 0.78
BMI, mean (SD), kg/m2 25.8 (4.4) 25.4 (3.8) 26.3 (4.8) 27.6 (6.2) 0.04
Ethnicity, non-Caucasian n(%) 16 (5) 6 (3) 6 (5) 4 (19) 0.003
Characteristics of HCV infection
Estimated duration of infection, median (range), years 13 (1–60) 13.5 (1–48) 13.5 (1–41) 10 (1–60) 0.95
HCV-RNA at baseline, mean (SD), log10 IU/mL 6.0 (0.9) 6.1 (0.8) 6.0 (0.9) 5.8 (1.0) 0.33




38/75 (34/66) 5/16 (24/76) 0.32





Cirrhosis, n(%) 43 (13) 23 (12) 15 (13) 5 (24) 0.29
Liver interface hepatitis Ishak grade, 0/1/2/3/4, n 20/104/127/74/
6
15/58/79/43/2 4/41/39/27/2 1/5/9/4/2 0.61
Liver lobular inflammation Ishak grade, 0/1/2/3/4, n 1/72/194/61/3 1/41/121/32/2 0/25/66/21/1 0/6/7/8/0 0.69
Liver portal inflammation Ishak grade, 0/1/2/3/4, n 14/154/135/28/
0
9/96/71/21/0 5/48/55/5/0 0/10/9/2/0 0.82
Liver steatosis score, 0/1/2/3, n 113/128/54/36 77/68/33/19 31/54/15/15 5/6/6/4 0.07
APRI-score, mean (SD), score 1.1 (1.2) 1.0 (1.1) 1.0 (1.0) 1.52 (2.1) 0.18
Treatment regimens and response
12/24week Peg-IFN + ribavirin, n(%) 163/168 (49.2/
50.8)
103/94 (52/48) 50/63 (44/56) 10/11 (48/52) 0.39
SVR rate, n(%) 224 (68) 132 (67) 82 (73) 10 (48) 0.08
Season
Sunny season at sampling n(%) 226 (68) 143 (73) 71 (63) 12 (57) 0.10
Host geneticsa






38/53/15 (36/50/15) 7/6/4(35/35/24) 0.78






17/56/32 (16/53/30) 1/11/5 (6/65/29) 0.34






39/53/14 (37/50/13) 8/6/3 (47/35/18) 0.76
Serum 25 (OH)D levels
Serum 25 (OH)D, mean (SD), nmol/L 58.9 (22.5)
<25 nmol/L, n(%) 9 (2.7)
> 75 nmol/L n(%) 75 (22.7)
HCV, hepatitis C virus; APRI, AST to platelet ratio; Peg-IFN, pegylated interferon; SD, standard deviation; SVR, sustained virologic response.a bOnly patients with
Caucasian ethnicity were included in the analysis.
https://doi.org/10.1371/journal.pone.0237840.t001
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HCV RNA quantification
HCV RNA was determined by qRT-PCR of plasma using Cobas AmpliPrep/COBAS TaqMan
HCV Test (Roche Diagnostics, Branchburg, NJ). Sustained virologic response was defined as
negative HCV-RNA 24 weeks after completion of therapy.
Measurement of 25(OH)D
Fasting serum samples was drawn from patients before treatment initiation. For determination
of serum concentration of 25(OH)D, a commercially available chemiluminiscence assay,
Architect 25-hydroxyvitamin D assay (Abbot diagnostics, Illinois USA) was used. The assay
does not discriminate between the two forms of vitamin D, i.e. Vitamin D3 cholecalciferol and
vitamin D2 ergocalciferol, and therefore measures the total amount of 25(OH)D.
Vitamin D related single nucleotide polymorphism assays
Polymorphisms were determined in serum by allelic discrimination real-time PCR using pre-
designed Taq-Man SNP Assays (Life Technologies, California USA) for rs7975232, rs2228570
and rs10877012 according to manufacturer’s instructions. rs7975232 (C>A) is also known as
ApaI and located in the VDR gene. rs2228570 (C>T) is known as FokI, is also located in the
VDR gene. rs10877012 (G>T) is located in the promotor region of the gene for CYP27B1.
Statistical methods
Continuous variables are presented as either mean with standard deviation or median with
range based on normal distribution and categorical values as frequencies with percentage.
Liver biopsy scores are presented as number of patients with a certain stage, grade, or score.
Differences in categorical variables were compared using either the χ2, Fisher’s exact test or
binominal regression. The ordinal data has been used as metric data, after consideration in
multiple regression, and also in some correlation analysis. Correlations were done with Pear-
son’s correlation for continuous and ordinal variables with normal distribution. Differences
between groups with continues and ordinal data were done with one-way analysis of variance
(ANOVA) test together with Tukey’s post hoc test. When comparing two groups a student T-
test was done. In the multivariate analysis for the association between Cirrhosis and vitamin
D, a multiple binominal logistic regression was performed. Multiple linear regression was
done to to evaluate variables in relation to fibrosis, steatosis and 25(OH)D. Parameters with a
p value of<0.1 were included in the multiple regression analysis. Single nucleotide polymor-
phisms were coded as 1, 2 or 3 in these analyses. For analysis of genetic data only Caucasian
patients were included in the analysis. All statistical analyses were performed using the IBM
SPSS statistics version 19 (IBM Corporation, Somers, NY) software package. All P-values are
two sided and values of<0.05 were considered statistically significant.
Season and UVB radiation data
Data of UVB radiation from the Swedish Metrological and Hydrological Institute (SMHI;
Norrköping, Sweden) was used to choose two periods in which the sun exposure differed the
most [25]. For Sweden, the least radiation was seen in the period from November to the end of
February. Since Norway, Finland and Denmark to a great extent overlap in latitude with Swe-
den, this data was used for all patients.
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Ethical considerations
The Regional Ethics Review Board in Gothenburg approved the study. All patients signed




Mean serum 25(OH)D concentration was 59 nmol/L, and there was a high percentage, 41%, of
patients with levels defined as potentially having a risk of deficiency, i.e.<50 nmol/L (equiva-
lent to 20 ng/L), but only 6% had a high risk of deficiency defined as<30 nmol/L (equivalent
of 12 ng/L). Interestingly, only 23% of patients had levels >75nmol/L, which the endocrinol-
ogy society defines as sufficient levels, Table 1. Lower 25(OH)D level groups were significantly
associated with non-Caucasian ethnicity, higher fibrosis stage, and higher BMI in univariate
analyses, Table 1. 25(OH) D concentration was not significantly different based on genetic var-
iations in rs2228570, rs7975232 and rs10877012, Table 2. Since ethnicity might have impacted
the result a separate analysis regarding baseline characteristics and fibrosis as well as 25 (OH)
D concentrations was performed with the only major difference being an association between
viral genotype and 25 (OH) D concentration, S1 Table.
Liver fibrosis
A significant, albeit weak correlation was observed for Ishak fibrosis stage and 25(OH)D con-
centrations (r = -0.10, p�0.05). Fibrosis stage and cirrhosis did not significantly differ between
25(OH)D groups, Table 1. However, mean 25(OH)D level was significantly lower in cirrhotic
compared to non-cirrhotic patients, although this difference was modest (52 ±18 vs. 60 ±23
nmol/L, p = 0.03), Fig 1A. The association was no longer significant in a binominal logistic
regression analysis, including season at sampling, BMI, gender, APRI-score and age, indicating
that 25(OH)D level was not independently associated with cirrhosis in this study, Table 3. Sim-
ilarly, 25(OH)D did not correlate with the non-invasive fibrosis indices GUCI, APRI, or FIB-4,
Fig 1C–1E. The fibrosis score was not significantly different based on genetic variations in
rs2228570, rs7975232 and rs10877012, Table 2.
Liver inflammation
25(OH)D status was also analyzed in relation to the various forms of liver inflammation, i.e.
portal inflammation, lobular inflammation and interface hepatitis with no significant differ-
ences noted. Also, no correlations were observed between 25(OH)D concentrations and
serum concentrations of normalized alanine aminotransferase (nALT) and normalized aspar-
tate aminotransferase (nAST), i.e. the ratio between measured ALT or AST and the upper
limit of normal, Fig 2A–2E.
Liver steatosis
25(OH)D did not differ between the steatosis grade groups (no steatosis, mild steatosis and
moderate-to-severe steatosis) when analyzing all the patients. Since infection with HCV geno-
type 3 is associated with markedly more pronounced steatosis, HCV genotypes 2 and 3 where
analyzed separately. In a one-way analysis of variance (ANOVA) for patient infected with
HCV genotype 2, there was a significant difference in 25(OH)D concentration between steato-
sis grade groups (F (2,91) = 4.4, p = 0.01). The difference was only significant when comparing
patients with no steatosis and moderate-to-severe steatosis, (60 ±20 vs. 39 ±12 nmol/L,
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p = 0.01), but a similar, non-significant trend was noted between mild steatosis and moderate-
to-severe steatosis, (55 ±18 vs. 39 ±12 nmol/L, p = 0.08). No such difference was observed
among genotype 3 infected patients, Fig 3A. Vitamin D levels demonstrated clear correlations
with BMI and fasting triglycerides, whereas only a non-significant trend was observed for
homeostatic model assessment (HOMA) score, Fig 3B–3D.
Seasonality
Based on data from the Swedish metrological and hydrological institute, a high UV exposure
period from March to October and a low sun exposure period from November to February
were chosen. 25(OH)D levels were significantly higher in patients sampled March-October
compared to November-February (61 ±23 vs. 54 ±21 nmol/L, p<0.01), and this was also signif-
icant for non-cirrhotic patients (63 ±24 vs. 54 ±20 nmol/L, p<0.01). Also, a similarly non-sig-
nificant difference was observed for the cirrhotic patients (53 ±18 vs. 47 ±17 nmol/L, p = 0.35),
Fig 4A. When plotting 25 (OH) values and UVB radiation at time of sampling (monthly UV
radiation values in Norrköping, Sweden), as expected, vitamin D values increased during the
Table 2. Associations of baseline characteristics with 25 (OH) D concentrations and fibrosis.
Feature Associations of Baseline Characteristics and 25 (OH) D
concentrations
Associations of Baseline Characteristics and fibrosis













Age, years -0.12 -0.06 0.3 0.05 0.44 <0.001 0.05 0.34 <0.001
Sex (female) 0.03 0.00 1.0 -0.40 -0.13 0.02 -0.13 -0.04 0.4
BMI, kg/m2 -0.98 -0.19 0.001 -0.97 -0.19 0.001 0.06 0.19 0.001 0.05 0.14 0.005
Ethnicity, (non-Caucasian) -14.42 -0.14 0.01 -15.86 -0.15 0.005 -0.16 -0.02 0.7
Characteristics of HCV
infection
HCV-RNA at baseline, log10
IU/mL
1.73 0.07 0.23 0.34 0.20 <0.001 0.06 0.04 0.5
HCV genotype, genotype 2/3 3.88 0.08 0.16 -0.1 1 -0.03 0.5
Liver firosis Ishak, score -1.69 -0.11 �0.05 -1.47 -0.10 0.08
Liver Ishak inflammation,
sum of score
-0.92 -0.08 0.16 0.54 0.70 <0.001a
Liver Ishak steatosis, score -2.05 -0.09 0.11 0.34 0.23 <0.001 0.03 0.02 0.7
APRI-score (log10) -1.89 -0.03 0.6 2.05 0.49 <0.001 1.69 0.41 <0.001
Season




-0.38 -0.01 0.83 -0.14 -0.06 0.3
Vitamin D3 receptor Gene
rs7975232 CC/AC/AA
-1.63 -0.05 0.37 -0.16 -0.07 0.2
CYP27B-1260 Gene Promotor
rs10877012 TT/TG/GG
-2.07 -0.06 0.27 -0.01 -0.006 0.9
Serum 25 (OH)D levels
Serum 25 (OH)D, nmol/L -0.01 -0.11 �0.05 -0.00 -0.02 0.6
HCV, hepatitis C virus; APRI, sat to platelet ratio. aExcluded from multiple regression due to multicollinearity. bOnly patients with Caucasian ethnicity were included in
the analysis.
https://doi.org/10.1371/journal.pone.0237840.t002
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summer months and peaked in late summer and early fall, Fig 4B. A majority of patients were
sampled during the period with high UV radiation.
Virology
No difference in serum 25(OH)D concentrations were observed between patients infected
with HCV genotype 2 as compared to genotype 3 (56 ±19 vs. 60 ±24 nmol/L, p = 0.18), and no
correlation with baseline HCV RNA level was observed (r = 0.66, p = 0.23). Likewise, there
were no significant differences in the likelihood of achieving a cure, i.e. sustained virologic
response (SVR), following interferon-based HCV therapy in the sufficient, potential risk of
insufficiency and higher risk of insufficiency groups, Table 1. Patients achieving SVR also had
similar serum 25(OH)D concentration compared to treatment failures (60 ±23 vs 58 ±22
nmol/L, p = 0.52).
Fig 1. 25-hydroxy vitamin D and liver fibrosis. Bar chart for 25-hydroxy vitamin D and liver cirrhosis (A) and scatter plots for 25-hydroxy vitamin D and
Ishak fibrosis stage (B) fibrosis indices GUCI-score (C), APRI-score (D) and Fib-4 score (E). Mean concentration and 95% confidence interval is shown.
Statistical significance determined by Student T test and Pearson’s test.
https://doi.org/10.1371/journal.pone.0237840.g001
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Multiple regression analysis for 25(OH)D concentration and fibrosis
Linear and multiple linear regression was calculated to further analyze associations with 25
(OH)D concentration and fibrosis. Variables with a p-value of less than 0.1 in the linear regres-
sion were included in the multiple regression analysis. For 25(OH)D concentration included
variables were BMI, ethnicity, fibrosis and season at sampling. The highest significant stan-
dardized beta coefficient in the multiple regression (β-value), indicating the highest impact on
variations in 25(OH)D concentration was seen for BMI, but this value was similar to those for
ethnicity and season at sampling, whereas the significant association between fibrosis and 25
(OH)D concentration vanished in this analysis. 25(OH)D concentration was likewise not sig-
nificantly associated with fibrosis in the multiple regression analysis for explaining fibrosis
severity, Table 2.
Discussion and conclusion
The main findings in this study were: i) Liver fibrosis correlated weakly with 25(OH)D con-
centration and cirrhotic patients had significantly lower levels of 25(OH)D in univariate analy-
ses, although this significance was lost in multivariate analyses. ii) Forty percent of
Scandinavian patients with chronic HCV genotype 2 or 3 infection are at potential risk of vita-
min D deficiency (<50 nmol/L of 25(OH)D) and 78% had values<75nmol/L but high risk of
deficiency (<30 nmol/L) was uncommon (�6%). iii) 25(OH)D levels were highly significantly
and independently inversely associated with BMI and non-Caucasian ethnicity. iv) There are
significant seasonal variations in 25(OH) D concentrations in HCV genotype 2 or 3 infected
patients in northern Europe.
In the present study, hepatic fibrosis stage was assessed by means of liver biopsies centrally
evaluated using the Ishak protocol by two experienced physicians reaching consensus scores,
which likely yielded high consistency, as previously documented [26]. Despite this and the sta-
tistical power of 331 enrolled patients, fibrosis stage did not independently correlate with 25
(OH)D concentrations. Cirrhotic patients had significantly lower vitamin D levels but when
accounting for covariates, e.g. BMI, in multivariate analyses, the significant association
between cirrhosis and 25(OH)D levels observed in univariate analyses vanished. However, it
should be noted that despite the findings in the present study, there may be an association in
Table 3. Differences in baseline characteristics according to cirrhosis.
Feature Cirrhosis No cirrhosis Odds ratio
(95% CI)
Unadjusted P-value Adjusted odds ratio
(95% CI)
Adjusted P-value
n = 43 n = 288
Epidemiological features
Age, mean (SD), years 50.7 (10.5) 40.6 (8.9) 1.1 (1.1–1.1) <0.0001 1.1 (1.1–1.2) <0.0001
Sex male n(%) 32 (74) 168 (58) 2.1 (1.0–4.3) 0.05 2.2 (0.9–5.6) 0.09
BMI, mean (SD), kg/m2 28.2 (3.9) 25.5 (4.3) 1.1 (1.1–1.2) 0.0002 1.1 (1.0–1.3) 0.004
Characteristics of HCV infection
HCV-RNA at baseline, mean SD, log10 IU/mL 6.3 (0.7) 6.0 (0.9) 1.4 (0.9–2.1) 0.15
HCV genotype n (%), genotype 2/3 13/30 (30/70) 81/206 (28/72) 1,1 (0.5–2.2) 0.79
APRI-score, mean (SD), score 2.1 (1.6) 0.9 (1.0) 1.8 (1.4–2.2) <0.0001 1.7 (1.3–2.1) <0.0001
Serum 25 (OH)D levels
Serum 25 (OH)D, mean (SD), nmol/L 51.7 (17.6) 60.0 (23.0) 0.7 (0.5–1.0)� 0.03 0.8 (0.5–1.3)� 0.35
HCV, hepatitis C virus; APRI, ast to platelet ratio; SD, standard deviation. �Odds ratio calculated from standard score of 25 (OH)D.
https://doi.org/10.1371/journal.pone.0237840.t003
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patients with decompensated cirrhosis (Child-Pugh B or C) as previously reported [27], or in
non-Caucasian patients, who have an established higher risk of vitamin D deficiency. The for-
mer group was excluded from enrollment in the NORDynamIC study as interferon therapy is
contraindicated in decompensated cirrhosis [28], and the latter group was relatively small (16
of 331 patients were non-Caucasian in the study) making it challenging to obtain robust statis-
tical results. In less severe liver disease, the hydroxylation to 25(OH)D in the liver might still
be sufficient to maintain serum concentrations of 25(OH)D, and an effect would likely be
more evident when liver function is failing as in patients with decompensated cirrhosis. Thus,
our results might have differed if patients with Child-Pugh B or C cirrhosis also had been
enrolled in the study, but aside from being interferon-intolerant, decompensated cirrhotic
patients often have contraindications to ordinary percutaneous liver biopsy, e.g. severe throm-
bocytopenia or coagulopathy [29].
A recent study evaluating the 25(OH)D levels in healthy Swedish blood donors reported a
mean concentration of 61 nmol/L with high seasonal variations, and also noted that 35% had
values<50 nmol/L and 75%<75 nmol/L [30]. In the present study, similar levels were
observed indicating that patients enrolled in the NORDynamIC study, despite approximately
half having significant liver fibrosis (Ishak stage�3), did not differ substantially from healthy
Fig 2. 25-hydroxy vitamin D and liver inflammation. Bar chart for 25-hydroxy vitamin D and portal inflammation (A), lobular inflammation (B),
interface hepatitis (C) and scatter plots for 25-hydroxy vitamin D and normalized ALT (D) and AST (E). Mean concentration and 95% confidence interval
is shown. Statistical significance determined by Student T test, One Way ANOVA and Pearson’s test.
https://doi.org/10.1371/journal.pone.0237840.g002
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blood donors regarding vitamin D status. However, it should be noted that in northern Europe
UVB radiation differs over the year, with exceptionally low values observed from November
until February. During this season, humans rely on stored reserves, dietary intake, and/or sup-
plementation of vitamin D. The result of the present study is somewhat alarming as 5% of
patients had levels <25 nmol/L during this period, and may have benefitted from
Fig 3. 25-hydroxy vitamin D and liver steatosis. Bar chart for 25-hydroxy vitamin D and liver steatosis severity is shown for the different hepatitis C virus genotypes (A).
Also scatter plots for 25-hydroxy vitamin D and fasting triglycerides (B), HOMA-score (C) and BMI (D) are shown. Mean concentration and 95% confidence interval is
shown. Statistical significance determined by One Way ANOVA and Pearson’s test.
https://doi.org/10.1371/journal.pone.0237840.g003
Fig 4. 25-hydroxy vitamin D and season. Bar chart for 25-hydroxy vitamin D and seasonal variation shown for all patients, cirrhotics and non cirrhotics (A) and monthly
variations together with UVB radiation are shown (B). Mean concentration and 95% confidence interval is shown for (A) and mean and standard error of mean for (B).
Statistical significance determined by Student T test.
https://doi.org/10.1371/journal.pone.0237840.g004
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supplementation, irrespective of symptoms, according to current Swedish guidelines [31].
This of course also applies to healthy Swedish blood donors where a study showed that levels
<25 nmol/L were around 9% during this same period [30]. In contrast to these findings,
another study from northern Sweden reported that only 0.7% had values<25 nmol/L, albeit
that all participants were sampled from January to April 2009 [32]. The latter study used high
pressure liquid chromatography with tandem mass spectrometry, which is considered the
golden standard. Chemiluminiscence immunoassays, as used in this study and in many rou-
tine laboratories, tend to overestimate the proportion of 25(OH)D deficient patients, which is
important to consider when interpreting the high percentage of low vitamin D levels [33]. The
comparable proportion of 25(OH)D deficiency in our study patients compared to blood
donors do not support general screening for deficiency among HCV infected patients with
compensated liver disease.
Lower vitamin D levels have been seen in patients with autoimmune hepatitis with marked
inflammation in liver biopsies [19]. Vitamin D also appears to have anti-inflammatory proper-
ties [34]. No such correlation between 25(OH)D and inflammation grade or any significant
differences in 25(OH)D depending on grade of interface hepatitis, lobular inflammation, por-
tal inflammation or elevated liver enzymes were detectable in the present study. The proposed
anti-inflammatory effect of vitamin D thus does not seem to have any major impact on inflam-
mation driven by chronic HCV genotype 2 or 3 infection.
Steatosis was analyzed based on HCV genotype, as HCV genotype 3 infection is known to
be associated with more severe steatosis [35, 36]. HCV genotype 2 infected patients with mod-
erate-to-severe steatosis had significantly lower vitamin D levels compared to patients with no
steatosis. However, only eight HCV genotype 2 infected patients had moderate-to-severe stea-
tosis, and thus this result should be interpreted cautiously. This difference was not observed in
genotype 3 infected patients likely due to the strong correlation between HCV viral load and
steatosis in genotype 3. Lower levels of 25(OH)D have been associated with non-alcoholic stea-
tohepatitis (NASH) as well as with non-alcoholic fatty liver disease (NAFLD), also when
accounting for features of the metabolic syndrome [10].
Polymorphisms in rs2228570 (Fok1), which causes a threonine-methionine change in the
VDR, and rs7975232 (ApaI), located in the 3’ untranslated region of the VDR gene, were not
associated with 25(OH)D concentration or fibrosis. As polymorphisms in both these SNPs
predominantly affect the function and abundance of the receptor for vitamin D, the lack of
association with serum 25(OH)D concentrations in the present study was not surprising and
corroborate prior observations [37], although contrasting with reported observations in a
pediatric cohort [38]. rs7975232 (ApaI) CC allele configuration alone and in combination with
rs1544410 (BsmI) and rs7311236 (TaqI) in the CCA haplotype, has also been shown to be asso-
ciated with fibrosis progression in patient with chronic HCV [20]. rs10877012 is situated in
the CYP27B-1260 gene promotor and responsible for conversion of 25(OH)D to active 1,25
(OH)D. These SNPs have been linked to 1,25(OH)D concentration [23]. No significant associ-
ations were noted between these SNPs and 25(OH)D or fibrosis, in contrast to a previous
report [23]. These three SNPs were chosen because they are thought to have an effect down-
stream of 25(OH)D through either influencing the receptor or the activation of vitamin D, but
they, like 25(OH)D concentration, all failed to have any independent association with fibrosis
stage. There are several SNPs involved in vitamin D signaling and metabolism, and a more
thorough screening would have been beneficial. For example, we only analyzed one of the
SNPs in the ApaI, BsmI and TaqI CCA haplotype, namely ApaI. However, recently BsmI and
TaqI, but not ApaI was shown to associate with fibrosis indices in patients with chronic HCV
[39].
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Vitamin D levels were highly significantly and independently inversely correlated to BMI,
and the impact of obesity on 25(OH)D concentration overshadowed other baseline character-
istics, including liver fibrosis. The importance of obesity for vitamin D deficiency has been pre-
viously well-established [40] and it has been suggested that lower vitamin D concentrations in
obese patients may be attributable to lower dietary intake [41], decreased sun exposure [42],
sequestering in adipose tissue [43, 44], and/or volumetric dilution [45]. The association
between obesity and cirrhosis in the absence of other causes of liver disease has also been dem-
onstrated [46, 47], although the underlying mechanisms remains to be fully elucidated. Other
important determinants of 25(OH)D concentration were ethnicity and season at sampling, in
accordance with prior reports [48, 49].
There are some limitations in this study. Most important is that patients with decompen-
sated liver cirrhosis were not included because of interferon intolerance, as a potential effect of
liver disease on 25(OH)D concentration most likely would be observed in such patients. The
study also is cross-sectional, and a longitudinal study would offer more reliable data especially
in a region like Scandinavia were UV-radiation differ much throughout the year. The preva-
lence of vitamin D deficiency was relatively low in our study, and if deficiency drives an accel-
eration in fibrosis progression, this could explain the lack of association between fibrosis and
25(OH)D, although this is controversial [50]. In order to address the potential relation
between vitamin D and liver fibrosis, large longitudinal prospective randomized trials span-
ning over decades with and without intervention with vitamin D supplementation would be
required.
Thus, in conclusion the present study demonstrated, as expected, significant seasonal varia-
tions in 25-hydroxy vitamin D concentrations in northern Europe, and that higher BMI and
non-Caucasian ethnicity were independently and strongly associated with lower serum vita-
min D concentrations, suggesting that they may have a stronger negative impact on 25(OH)D
levels than liver histopathology and other baseline characteristics in HCV genotype 2 or 3
infected patients with compensated liver disease.
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